Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial by Coghill, David R. et al.
                                                              
University of Dundee
Post hoc analyses of the impact of previous medication on the efficacy of
lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder
in a randomized, controlled trial
Coghill, David R.; Banaschewski, Tobias; Lecendreux, Michel; Soutullo, César; Zuddas,
Alessandro; Adeyi, Ben; Sorooshian, Shaw
Published in:
Neuropsychiatric Disease and Treatment
DOI:
10.2147/NDT.S68273
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Coghill, D. R., Banaschewski, T., Lecendreux, M., Soutullo, C., Zuddas, A., Adeyi, B., & Sorooshian, S. (2014).
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the
treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. Neuropsychiatric Disease
and Treatment, 10, 2039-2047. 10.2147/NDT.S68273
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
© 2014 Coghill et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution,   
and reproduction in any medium, provided the original author and source are credited.
Neuropsychiatric Disease and Treatment 2014:10 2039–2047
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2039
O r i g i N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/NDT.S68273
David r coghill1
Tobias Banaschewski2
Michel lecendreux3
césar soutullo4
alessandro Zuddas5
Ben adeyi6
shaw sorooshian7
1Division of Neuroscience, University 
of Dundee, Dundee, UK; 2child 
and adolescent Psychiatry and 
Psychotherapy, central institute 
of Mental health, Medical Faculty 
Mannheim, University of heidelberg, 
Mannheim, germany; 3Paediatric 
sleep centre and National reference 
centre for Orphan Diseases: 
Narcolepsy, idiopathic hypersomnia 
and Kleine-levin syndrome, robert-
Debré University hospital, Paris, 
France; 4child and adolescent 
Psychiatry Unit, Department of 
Psychiatry and Medical Psychology, 
University of Navarra clinic, 
Pamplona, spain; 5Department 
of Biomedical sciences, section 
of Neuroscience and clinical 
Pharmacology, University of cagliari, 
cagliari, italy; 6shire, Wayne, Pa, Usa; 
7shire, eysins, switzerland
correspondence: David r coghill
Division of Neuroscience, Ninewells’ 
hospital, University of Dundee, Dundee, 
DD1 9sY, UK 
Tel +44 13 8220 4004
Fax +44 13 8234 6555
email d.r.coghill@dundee.ac.uk 
Post hoc analyses of the impact of previous 
medication on the efficacy of lisdexamfetamine 
dimesylate in the treatment of attention-deficit/
hyperactivity disorder in a randomized,  
controlled trial
Background: Following the approval of lisdexamfetamine dimesylate (LDX) in several 
European countries for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 
children and adolescents with an inadequate response to methylphenidate (MPH) treatment, 
the aim of the present analysis was to establish the response to LDX in subgroups of patients 
with different ADHD medication histories.
Methods: This was a post hoc subgroup analysis of data from a 7-week, European, double-
blind, dose-optimized, Phase III study. Patients aged 6–17 years were randomized 1:1:1 to LDX, 
placebo, or osmotic-release oral system methylphenidate (OROS-MPH). OROS-MPH was 
included as a reference arm rather than as a direct comparator. Efficacy was assessed in patients 
categorized according to their ADHD medication history using the ADHD Rating Scale IV 
and Clinical Global Impressions-Improvement (CGI-I) scores.
Results: The difference between active drug and placebo in least-squares mean change from 
baseline to endpoint in ADHD Rating Scale IV total score (95% confidence interval) was 
similar between the overall study population (n=317; LDX, -18.6 [-21.5, -15.7]; OROS- 
MPH, -13.0 [-15.9, -10.2]) and treatment-naïve individuals (n=147; LDX, -15.1 [-19.4, -10.9]; 
OROS-MPH, -12.7 [-16.8, -8.5]) or patients previously treated with any ADHD medication 
(n=170; LDX, -21.5 [-25.5, -17.6]; OROS-MPH, -14.2 [-18.1, -10.3]). In addition, similar 
proportions of patients receiving active treatment were categorized as improved based on CGI-I 
score (CGI-I of 1 or 2) in the overall study population and among treatment-naïve individuals 
or patients previously treated with any ADHD medication.
Conclusion: In these post hoc analyses, the response to LDX treatment, and to the refer-
ence treatment OROS-MPH, was similar to that observed for the overall study population in 
subgroups of patients categorized according to whether or not they had previously received 
ADHD medication.
Keywords: attention-deficit/hyperactivity disorder, lisdexamfetamine dimesylate, 
methylphenidate, central nervous system stimulants
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is characterized by persistent symp-
toms of hyperactivity/impulsivity and/or inattention, and is estimated to affect approxi-
mately 5.9%–7.1% of children and adolescents worldwide.1,2 Previously thought to be 
limited to childhood, symptoms of ADHD are now believed to persist into adulthood 
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in approximately two thirds of patients.3,4 ADHD is associ-
ated with significant impairments in academic, social, and 
interpersonal functioning, highlighting the importance of 
effective therapeutic options.1,5 
Psychostimulants, including methylphenidate (MPH) and 
amphetamine, are recognized as effective pharmacological 
treatments for ADHD.1,6 In Europe, MPH is generally recom-
mended as the first-line medication for ADHD. The prodrug 
lisdexamfetamine dimesylate (LDX) is the first long-acting 
amphetamine-based ADHD medication to be approved in 
Europe, where it is licensed as a second-line therapy in sev-
eral countries for the treatment of children and adolescents 
who have experienced a clinically inadequate response to 
MPH therapy. LDX has been established as an effective and 
generally well tolerated treatment for children, adolescents, 
and adults with ADHD in multiple randomized, double-
blind, placebo-controlled trials.7–11 In a pivotal European, 
Phase III, double-blind, randomized controlled trial in 
children and adolescents with ADHD (study SPD489-325; 
ClinicalTrials.gov identifier NCT00763971), LDX signifi-
cantly improved ADHD symptoms compared with placebo, 
as assessed by the ADHD Rating Scale IV (ADHD-RS-IV) 
and Clinical Global Impressions-Improvement (CGI-I).10 In 
addition to the placebo arm, this European study included 
osmotic-release oral system MPH (OROS-MPH) as an active 
reference treatment (as opposed to a direct comparator) to 
provide study validation and contextualize results. Whilst 
the study was not designed to support a formal statistical 
comparison of the two active treatments, a subsequent post 
hoc analysis indicated that LDX was significantly more 
effective than OROS-MPH at improving ADHD-RS-IV 
scores (effect size 0.54; P0.001) and that a significantly 
(P0.05) greater proportion of patients receiving LDX 
were classified as treatment responders, based on two of 
the three response criteria examined, than those receiving 
OROS-MPH.12 
The present post hoc analyses examined the impact of 
previous ADHD medication on the efficacy of LDX treat-
ment in SPD489-325. Because of the recent second-line 
approval of LDX in several European countries, European 
patients being considered for LDX treatment should have 
received other ADHD medications, and for most this is likely 
to be an MPH-based formulation. Therefore, for clinicians 
in Europe, it is particularly important to establish the effi-
cacy of LDX in patients who have been previously treated 
with ADHD medication. The aim of this analysis was to 
establish whether the LDX treatment response for subgroups 
of patients with different ADHD treatment histories was 
similar to that of the overall study population. This analysis 
did not attempt to compare the relative effects of LDX and 
the reference treatment OROS-MPH within these patient 
subgroups because the small number of patients involved 
would limit the robustness of such analyses to support 
inferential statistics. 
Materials and methods
The design of study SPD489-325 has been described in detail 
previously.10 This randomized, double-blind, parallel-group, 
dose-optimized, placebo-controlled study was conducted in 
accordance with current applicable regulations, the Inter-
national Conference on Harmonisation of Good Clinical 
Practice, and local ethical and legal requirements. The study 
protocol was approved by an independent ethics committee/
institutional review board and regulatory agency in each 
center (as appropriate) before study initiation. Each patient’s 
parent or legal guardian provided written, informed consent, 
and, when appropriate, assent was obtained from each patient 
before commencing study-related procedures.
study population
This study enrolled male and female children and adolescents 
(aged 6–17 years) who satisfied the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) criteria for a primary diagnosis of ADHD, 
and who had a baseline ADHD-RS-IV total score of 28 or 
higher. Medication history was obtained at baseline. Patients 
were excluded from the study if they had previously failed to 
respond, based on the investigators’ judgment, to an adequate 
course (dose and duration) of OROS-MPH therapy or if their 
current ADHD medication provided effective control of 
symptoms with acceptable tolerability. In addition, individu-
als with documented allergy, hypersensitivity, or intolerance 
to amphetamines or MPH were excluded. All patients attended 
an initial screening visit which included documentation 
of their lifetime history of therapies for ADHD; use of 
any investigational compound, clonidine, antipsychotic, 
anxiolytic, sedative-hypnotic or antidepressant medication 
within 30 days prior to screening excluded a patient from 
the study. The use of herbal preparations or melatonin was 
prohibited during the study. Continued participation in 
behavioral therapy was permitted, provided that the patient 
had been receiving the therapy for at least one month at the 
time of the baseline visit. With the exception of oppositional 
defiant disorder, this study also excluded patients having a 
comorbid psychiatric diagnosis with significant symptoms 
and individuals with a conduct disorder.
Neuropsychiatric Disease and Treatment 2014:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2041
lDX in patients previously medicated for aDhD
study design
Following the initial screening visit (visit 1), participants 
completed a washout period (3–42 days); for all previous 
medications, the washout period was a minimum of five times 
the half-life of the medication. Eligible patients were then 
randomized (1:1:1) at baseline (visit 0) to receive once-daily 
LDX (30 mg, 50 mg, or 70 mg), placebo, or OROS-MPH 
(18 mg, 36 mg, or 54 mg) for a 7-week, double-blind, dose-
optimized evaluation period (visits 1–7). Investigators were 
not blinded to patients’ treatment history. The evaluation 
period was immediately followed by a one-week washout 
and a follow-up visit (visit 8). Endpoint was defined as the 
last on-therapy, post-randomization visit at which a valid 
efficacy score was obtained.
Efficacy assessments
The primary efficacy outcome in study SPD489-325 was 
the change in ADHD-RS-IV total score from baseline 
to endpoint.13 This assessment scale consists of 18 items 
designed to reflect current ADHD symptoms and the total 
score ranges from 0 to 54. ADHD-RS-IV assessments were 
performed at baseline (visit 0) and all subsequent treat-
ment visits by a physician experienced in the evaluation 
of children and adolescents with ADHD. A decrease from 
baseline in ADHD-RS-IV score indicates improvement in 
ADHD symptoms.
The key secondary efficacy outcome utilized the 
CGI scale,14 which permits a global evaluation of the patient’s 
severity of illness and improvement over time. CGI-I was 
assessed at all post-baseline visits to rate the patient’s 
improvement from baseline using a 7-point scale ranging 
from 1 (very much improved) to 7 (very much worse). 
Patients were categorized as “improved” (defined as a CGI-I 
score of 1 [very much improved] or 2 [much improved]) or 
“not improved” (all other scores), and results were expressed 
as the percentage of improved patients at endpoint. The CGI 
assessments were completed by a physician experienced in 
the evaluation of children and adolescents with ADHD. 
In these post hoc analyses, changes in ADHD-RS-IV 
total scores and in the percentage of patients categorized as 
“improved” on the basis of CGI-I scores were assessed for 
patients dichotomized according to previous treatment with 
ADHD medication (treatment-naïve or previously treated). 
In addition, changes in ADHD-RS-IV total scores were 
examined specifically in patients who had reported that they 
had previously received MPH treatment at any time, and 
in those who had reported receiving MPH treatment in the 
period immediately prior to randomization in SPD489-325 
(defined as having received MPH treatment at any point 
during the 30 days prior to randomization).
statistical analysis
The safety population comprised all patients who were 
randomized and received at least one dose of investigational 
product. The full analysis set was defined as all patients 
who were randomized and received at least one dose of 
investigational product but excluded 15 patients from one 
site owing to violations of good clinical practice. Dosing 
information and efficacy outcomes were assessed in the 
full analysis set. Statistical analyses included the calcula-
tion of least-squares means, which were based on type III 
sum of squares from an analysis of covariance model for 
the change from baseline in ADHD-RS-IV total score, 
including treatment, country, and age groups as fixed effects 
and baseline value as a covariate. The precision of results 
and the similarities between subgroups were estimated 
based on 95% confidence intervals. Effect sizes were cal-
culated as the difference between the least-squares mean 
scores for the active treatment and placebo groups, divided 
by the root mean square error obtained from the analysis 
of covariance model. Effect sizes of 0.2, 0.5, and 0.8 cor-
respond to small, medium, and large magnitudes of effect, 
respectively.15 OROS-MPH was included in SPD489-325 
as an active reference arm in order to provide internal 
validation of the study design. However, SPD489-325 was 
not designed or powered to support a formal statistical 
comparison between LDX and OROS-MPH or between 
treatment-naïve patients and those who had previously 
received ADHD medication.
Results
Patient disposition and baseline 
characteristics
Patient disposition and baseline characteristics for the overall 
study population have been fully described previously and 
were similar across the three treatment groups (Table 1).10 
A total of 336 patients were enrolled in ten European coun-
tries and the full analysis set comprised 317 patients (LDX, 
n=104; placebo, n=106; OROS-MPH, n=107). The study 
was completed by 196 individuals (LDX, n=80; placebo, 
n=42; OROS-MPH, n=74). Table 2 lists the medications 
previously used to treat ADHD in any treatment group and 
the numbers of patients that received each medication. The 
most common previous medication was methylphenidate, 
which had been used by 158 of the 182 previously treated 
patients included in the safety population (86.8%). Patients 
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who had not previously received any of the medications listed 
in Table 2 were considered treatment-naïve.
Efficacy: Any previous ADHD  
medication group
Mean ADHD-RS-IV total scores at baseline were similar 
in treatment-naïve patients and those who had previously 
received any ADHD medication. In all subgroups of patients, 
mean ADHD-RS-IV total scores decreased from baseline to 
endpoint (Figure 1). Based on 95% confidence intervals, the 
difference between active treatment (LDX or OROS-MPH) 
and placebo in least-squares mean change from baseline to 
endpoint in ADHD-RS-IV total score did not differ from 
that of the overall study population in both treatment-naïve 
patients and those who had previously received any ADHD 
medication (Figure 1). Effect sizes indicated robust treatment 
effects in all previous treatment subgroups. However, effect 
sizes were numerically larger in previously treated patients 
than in treatment-naïve individuals (Figure 1). 
Compared with placebo, there were also a greater proportion 
of patients with an improved CGI-I score (CGI-I score of 1 or 2) 
at endpoint in the LDX treatment group and in the OROS-MPH 
reference arm, in both treatment-naïve and previously treated 
patients (Table 3). The differences between active drug and pla-
cebo in the percentage of improved patients at endpoint in each 
subgroup did not differ from the overall study population. 
Previous MPh treatment group
Mean (standard deviation) ADHD-RS-IV total scores at base-
line were similar across treatment groups in treatment-naïve 
patients and in those who had previously received MPH, 
either at any time or immediately prior to randomization 
(Figure 1). The differences (active drug minus placebo) 
in least-squares mean change from baseline to endpoint in 
ADHD-RS-IV total scores in patients previously treated with 
MPH, either at any time or immediately prior to randomiza-
tion, were similar to those of the overall study population 
based on 95% confidence intervals (Figure 1). Effect sizes 
indicated robust treatment effects in previously MPH-treated 
patients and, like patients who had previously received any 
ADHD medication, effect sizes in these subgroups were 
numerically larger than in treatment-naïve individuals.
effect of previous treatment on optimal 
doses of lDX and OrOs-MPh
The different previously treated subgroups each received 
similar mean (standard deviation) doses of LDX (overall 46.1 
[11.87] mg/day, n=104; treatment-naïve 44.4 [11.65] mg/day, 
n=47; previously treated 47.5 [11.96] mg/day, n=57; pre-
viously MPH treated 47.1 [12.15] mg/day, n=49; MPH 
immediately prior to randomization 49.2 [10.70] mg/day, 
n=29) or OROS-MPH (overall 37.5 [10.06] mg/day, n=107; 
treatment-naïve 37.0 [9.81] mg/day, n=49; previously treated 
37.9 [10.32] mg/day, n=58; previously MPH treated 38.5 
[10.13] mg/day, n=51; MPH immediately prior to 
randomization 38.7 [10.14] mg/day, n=22). 
Discussion
Establishing the efficacy of LDX among previously treated 
patients is of clinical relevance in Europe, where LDX 
Table 1 Baseline demographics (safety population)a
Characteristic LDX (n=111) Placebo (n=110) OROS-MPH (n=111)
age, years, mean (sD) 10.9 (2.9) 11.0 (2.8) 10.9 (2.6)
sex, male, n (%) 87 (78.4) 91 (82.7) 90 (81.1)
race, white, n (%) 107 (96.4) 108 (98.2) 107 (96.4)
BMI, kg/m2, mean (sD) 19.3 (3.7) 19.0 (3.3) 19.1 (3.2)
Baseline aDhD-rs-iV total score, mean (sD)b 41.0 (7.3) 41.2 (7.2) 40.4 (6.8)
Baseline cgi-s rating, mean (sD)b 5.0 (0.8) 4.9 (0.8) 5.0 (0.8)
aDhD subtype, n (%)c
Predominantly inattentive 23 (20.7) 16 (14.5) 14 (12.7)
Predominantly hyperactive-impulsive 2 (1.8) 7 (6.4) 1 (0.9)
combined 86 (77.5) 87 (79.1) 95 (86.4)
Time since aDhD diagnosis, yearsc
Mean (sD) 2.4 (2.9) 2.2 (2.6) 2.2 (2.5)
Median (range) 1.3 (0.0–10.9) 0.90 (0.0–10.2) 0.8 (0.0–9.0)
Notes: adapted from coghill D, Banaschewski T, lecendreux M, et al. european, random ized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents 
with attention-deficit/hyperactivity disorder. Eur Neurop sychopharmacol. 2013;23(10):1208–1218.10 aDemographic and baseline characteristics have previously been reported 
in detail; bfive patients had no baseline ADHD-RS-IV total score or CGI-S rating; cone patient in the OrOs-MPh group was not evaluated for aDhD subtype or time since 
aDhD diagnosis; percentages are based on the number of patients in each treatment group.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD Rating Scale IV; BMI, body mass index; CGI-S, Clinical Global Impressions-Severity; 
lDX, lisdexamfetamine dimesylate; OrOs-MPh, osmotic-release oral system methylphenidate; sD, standard deviation.
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is approved for use for patients with ADHD who have 
responded inadequately to MPH. In this randomized, con-
trolled trial, approximately half (54.8%) of patients in the 
study had received previous ADHD medication and, of these, 
the majority (158/182 patients; 86.8%) had received MPH. 
The present post hoc analyses indicated that the response 
to LDX treatment was similar in subgroups of patients cat-
egorized according to whether or not they had previously 
received ADHD medication, and was similar to that observed 
for the overall study population. 
Several lines of evidence indicate that the outcome of 
treatment with one ADHD medication does not predict 
the success of treatment with a second.16 The Multimodal 
Treatment Study of Children with ADHD (MTA) examined 
potential moderators of treatment response and concluded 
that previous medication did not predict future response to 
medication.17,18 In addition, crossover trials have demon-
strated differential clinical responses for individuals treated 
sequentially with MPH and amphetamines or vice versa.19,20 
The present findings are also consistent with a previous 
post hoc analysis of a US-based, randomized, double-blind 
study that indicated that the efficacy of LDX treatment was 
similar in the subgroup of patients who were receiving MPH 
treatment at study entry and the overall study population.21 
Finally, a head-to-head, randomized, double-blind study 
comparing LDX and atomoxetine demonstrated a robust 
LDX treatment effect among patients who had previously 
responded inadequately to MPH.22 
In the present study, the response to LDX was robust 
in all subgroups, as indicated by the large effect sizes for 
the reduction in ADHD-RS-IV total score. However, effect 
sizes were larger in previously treated patients than among 
treatment-naïve individuals. Analysis of ten randomized, 
placebo-controlled trials assessing the efficacy of the 
nonstimulant ADHD medication atomoxetine in children 
indicated that a placebo response was more likely in treat-
ment-naïve children than in patients who had previously been 
treated with ADHD medication.23 In the present analysis, 
the response to placebo was also numerically greater in the 
treatment-naïve subgroup than in previously treated patients 
Table 2 summary of lifetime aDhD medications (safety population) 
LDX  
(n=111) n (%)
Placebo 
(n=110) n (%)
OROS-MPH 
(n=111) n (%)
Total 
(n=332) n (%)
any selected aDhD medication 64 (57.7) 58 (52.7) 60 (54.1) 182 (54.8)
Methylphenidate or methylphenidate hydrochloride 56 (50.5) 49 (44.5) 53 (47.7) 158 (47.6)
atomoxetine or atomoxetine hydrochloride 17 (15.3) 15 (13.6) 10 (9.0) 42 (12.7)
risperidone 7 (6.3) 3 (2.7) 6 (5.4) 16 (4.8)
amphetamine sulfate 3 (2.7) 7 (6.4) 5 (4.5) 15 (4.5)
carbamazepine 1 (0.9) 1 (0.9) 2 (1.8) 4 (1.2)
imipramine or imipramine hydrochloride 1 (0.9) 1 (0.9) 1 (0.9) 3 (0.9)
Tiapride hydrochloride 2 (1.8) 1 (0.9) 0 (0.0) 3 (0.9)
chloroprothixene or chloroprothixene 
hydrochloride
1 (0.9) 0 (0.0) 1 (0.9) 2 (0.6)
Piracetam 1 (0.9) 0 (0.0) 1 (0.9) 2 (0.6)
Valproate sodium or valproic acid 1 (0.9) 0 (0.0) 1 (0.9) 2 (0.6)
amitriptyline 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
clomipramine 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
cyroheptadine 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Desipramine 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
ergenyl chrono 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
Fluvoxamine 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
haloperidol 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
lamotrigine 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Omega-3 fatty acids 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Perazine 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
sedariston 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.3)
sertraline hydrochloride 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.3)
Thioridazine 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.3)
Topiramate 1 (0.9) 0 (0.0) 0 (0.0) 1 (0.3)
Zappelin 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.3)
Notes: Patients may have been previously treated with more than one aDhD medication during their lifetime but were only counted once in each drug category. all 
medication names are based on the terminology provided by the individual study investigators.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; LDX, lisdexamfetamine dimesylate; OROS-MPH, osmotic-release oral system methylphenidate.
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(for both ADHD-RS-IV and CGI-I assessments) and this is 
likely to have contributed to the smaller effect size in the 
treatment-naïve subgroup. 
The OROS-MPH active reference arm was included 
in SPD489-325 to provide internal validation of the study 
design and to contextualize results. A previous post hoc anal-
ysis compared the relative benefits of LDX and  OROS-MPH 
treatment in the overall SPD489-325 study population, 
finding that LDX was significantly more effective than 
OROS-MPH on several treatment outcomes.12 However, 
the conclusions of this analysis should be considered in 
light of its post hoc nature.12 It should also be noted that 
the maximum permitted dose of OROS-MPH in Europe is 
54 mg/day, which is lower than the 72 mg/day permitted 
Figure 1 change in aDhD-rs-iV total scores from baseline to endpoint in treatment-naïve and previously treated patients (full analysis set).
Notes: aDhD-rs-iV total scores are shown as mean values ±95% cis. in the left hand panel, open symbols indicate mean baseline scores and closed symbols indicate mean 
endpoint scores (lDX, circles; placebo, triangles; OrOs-MPh, squares). The difference (active drug minus placebo) in ls mean change (±95% ci) from baseline to endpoint 
is also shown (lDX, circles; OrOs-MPh, squares). gray shading on the left hand panel indicates the 95% ci for the mean aDhD-rs-iV total score at endpoint in the lDX 
group in the overall study population. On the right hand panel, gray shading indicates the 95% ci for the difference (lDX minus placebo) in ls mean change from baseline to 
endpoint in the overall study population. Endpoint is the last on-therapy assessment visit with a valid ADHD-RS-IV total score. Immediately prior to randomization is defined 
as up to 30 days prior to randomization.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD rating scale IV; CI, confidence interval; LDX, lisdexamfetamine dimesylate; LS, least-
squares; MPh, methylphenidate; OrOs-MPh, osmotic-release oral system MPh.
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in other regions and which may have limited its efficacy.12 
The current analysis makes no attempt to compare the rela-
tive benefits of LDX and OROS-MPH in patient subgroups 
because the patient numbers involved were too small to 
support inferential statistics.
Because the study excluded patients who were well 
controlled on their current medication with acceptable tol-
erability, it is noteworthy that OROS-MPH was similarly 
effective in the overall study population and in patients 
who had previously received MPH therapy. One possible 
explanation for this is that the dosage of previous treatment 
was suboptimal, whereas in the present study both active 
treatments were dose-optimized. A second possibility is 
that the formulation of MPH may have differed between 
the study drug, OROS-MPH, and previous MPH treat-
ment. For example, patients may previously have received 
short-acting MPH which has been associated with lower 
levels of treatment adherence than once-daily, long-acting 
formulations such as OROS-MPH.24 Finally, it was evident 
in the MTA study that an MPH treatment regimen delivered 
within a controlled clinical trial setting was significantly 
more effective than treatment as usual within a commu-
nity care setting, even though most patients undergoing 
community care were treated with MPH,18 indicating that 
the care and support provided in a clinical trial setting is 
likely to produce enhanced treatment benefits compared 
with the same treatment in the absence of such support. 
Further interpretation of this result is limited owing to the 
lack of information about why previous medications were 
discontinued.
Full safety outcomes from this study have been published 
previously10,12 and were not examined further in the present 
post hoc analyses. In summary, the proportion of patients 
reporting treatment emergent adverse events was 72.1% 
in the LDX treatment group, 57.3% in the placebo group, 
and 64.9% in the OROS-MPH group. Low proportions of 
patients reported serious treatment emergent adverse events 
across all treatment groups (LDX, 2.7%; placebo, 2.7%; 
OROS-MPH, 1.8%) and few patients experienced treatment 
emergent adverse events leading to discontinuation (LDX, 
4.5%; placebo, 3.6%; OROS-MPH, 1.8%).
When interpreting the LDX treatment response in these 
analyses, it should be noted that study SPD489-325 was not 
powered to detect significant effects between subgroups and, 
although the subgroups examined here were based on preran-
domization patient characteristics, they were not prespecified. 
In addition, it is unclear whether the specific inclusion and 
exclusion criteria relating to previous medication response/
exposure would have impacted on the LDX treatment 
response. The short-term nature of this study and the exclu-
sion of patients with comorbidities may limit the conclusions 
to be drawn from the present findings. Finally, the fact that 
safety outcomes were not assessed in the previously treated 
subgroups is another limitation of the present study. 
In conclusion, these post hoc analyses of a randomized, 
double-blind, placebo-controlled trial, which enrolled a large 
number of patients at multiple centers across Europe, support 
the use of LDX as an effective therapy for treatment-naïve 
children and adolescents with ADHD as well as those who 
have received previous ADHD medication.
Table 3 Proportions of improved patients (cgi-i score of 1 or 2) at endpoint (full analysis set)
Patient subgroups Percentage of improved 
patients (CGI-I 1 or 2) 
at endpoint (95% CI)
Difference in percentage of 
improved patients relative 
to placebo (95% CI)
Overall study population (n=317)
lDX (n=104) 78.0 (69.9, 86.1) 63.6 (53.0, 74.1)
Placebo (n=106) 14.4 (7.7, 21.2)
OrOs-MPh (n=107) 60.6 (51.2, 70.0) 46.2 (34.6, 57.7)
Patient subgroups based on medication history 
Treatment-naïve (n=147)
lDX (n=47) 80.4 (69.0, 91.9) 60.8 (45.0, 76.6)
Placebo (n=51) 19.6 (8.7, 30.5)
OrOs-MPh (n=49) 63.8 (50.1, 77.6) 44.2 (26.7, 61.8)
Previously treated with any aDhD medication (n=170)
lDX (n=57) 75.9 (64.5, 87.3) 66.5 (52.6, 80.3)
Placebo (n=55) 9.4 (1.6, 17.3)
OrOs-MPh (n=58) 57.9 (45.1, 70.7) 48.5 (33.4, 63.5)
Note: Endpoint was defined as the last on-therapy treatment visit with a valid assessment score.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CGI-I, Clinical Global Impressions-Improvement; CI, confidence interval; LDX, lisdexamfetamine dimesylate; 
OrOs-MPh, osmotic-release oral system methylphenidate.
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